Resistance to new anti-grampositive. Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France

Size: px
Start display at page:

Download "Resistance to new anti-grampositive. Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France"

Transcription

1 Resistance to new anti-grampositive agents Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France

2 Recently available antimicrobials against MDR Gram-positive infections Cyclic lipopeptide: daptomycin Oxazolidinone: linezolid Glycylcycline: tigecycline Under development: analogs of vancomycin and teicoplanin (dalbavancin oritavancin, telavancin), new cephalosporins (ceftobiprole), iclaprim

3 Tigecycline Tigecycline overcomes the 2 major resistance mechanisms of tetracycline: drug-specific efflux pump acquisition and ribosomal protection Wide spectrum, bacteriostatic Tigecycline MICs (mg/l) Range MIC50 MIC90 MSSA (813) MRSA (879) E. faecalis (740) E. faecium (280) Waites et al. Antimicrob Agents Chemother. 2006;50:

4 In vitro selection of MRSA mutants resistant to tigecycline Selection of MRSA (N315 and Mu3) mutants resistant to tigecycline after serial passages (n=16) (MIC=4 mg/l) Analysis of transcription profiles: 100-fold increased expression of a gene cluster, meprab (multidrug export protein) in mutants meprab encoded a MarR-like transcriptional regulator (mepr), a novel MATE family efflux pump (mepa), and a hypothetical protein of unknown function (mepb). Mutations of mepr gene in the mutants presumably inactivated the MepR repressor McAleese et al., Antimicrob Agents Chemother 2005, 49:

5 Efflux pumps in Gram-positive bacteria Piddock Nature Reviews Microbiology 4, (August 2006)

6 Daptomycin Daptomycin has a membrane-based mode of action calcium-dependent membrane depolarization of S. aureus and potassium release from. A model for the bactericidal action of daptomycin involving oligomerization of daptomycin and disruption of the functional integrity of the cytoplasmic membrane has been proposed.

7 Daptomycin: transcriptional profiling studies Potential dual mode of action of daptomycin involving both cell wall inhibition and membrane depolarization Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. Antimicrob Agents Chemother. 2008;52:

8 Correlation between reduced daptomycin susceptibility and vancomycin resistance in GISA/VISA Cui, L. Z., E. Tominaga, H. M. Neoh, and K. Hiramatsu Antimicrob. Agents Chemother. 50:

9 Resistance to daptomycin in Gram-positive organisms Daptomycin-resistant S. aureus and Enterococcus spp. during prolonged treatment with daptomycin has been reported (Fowler et al., N Engl J Med, 355:653 65; Hayden et al, J. Clin. Microbiol. 43:5285 7; Lewis et al., Antimicrob. Agents Chemother. 49: Munoz-Price et al, Clin. Infect. Dis. 41: ). Genome comparisons of susceptible and resistant laboratory-derived S. aureus identified mutations in various genes: mprf (a membrane lysylphosphatidylglycerol synthetase), yycg (a histidine kinase), and rpoc and rpob (subunits of RNA polymerase). Friedman, L., J. D. Alder, and J. A. Silverman Antimicrob. Agents Chemother. 50:

10 Oxazolidinone: linezolid Solubility (morpholine group) Activity Small molecule: MW (vancomycin 1500)

11 Binding of linezolid to 23S rrna (E. coli model) Leach et al. Mol Cell ;26:

12 Resistance to linezolid Unfrequent resistance by mutation of 23S rrna reported in enterococci and staphylococci: essentially G2576 mutation in clinical isolates. Bacteria have several copies of rrna operons. The copy number depends on the species. The level of resistance is proportional to the number of mutated RNA operon copies.

13 Number of 23S rrna genes in Gram-positive cocci S. pneumoniae 4 E. faecalis 4 S. aureus 5/6 S. agalactiae 6 S. pyogenes 6 E. faecium 6

14 Selection of linezolid-resistant mutants of E. faecalis JH2-2 and E. faecalis JH2-2 reca Linezolid MIC (mg/l) JH 2-2 JH 2-2 reca Day Boumghar-Bourtchai L, Leclercq R, Galopin S. Dhalluin A

15 Mutational resistance to linezolid E. faecalis No of passages Linezolid MIC (mg/l) G2576 mutation rrla rrlb rrlc rrld 0 2 G G G G JH G G G T 5 16 T G G T 6 32 T G G T 8 32 T G G/T T 0 2 G G G G JH2-2 reca 5 8 G G G T 6 8 G G G/T T Boumghar-Bourtchai L, Leclercq R, Galopin S. Dhalluin A 7 16 G G T T 8 16 G G T T

16 Linezolid dosage A single dose for everybody. from 40 kg to 200 kg.. Serum concentration of linezolid is proportional to the weight

17 Emergence of linezolid resistance in an in vitro pharmacodynamic model (Bacillus anthracis) Louie et al., Antimicrob Agents Chemother, 2008 June

18 Outbreak of Linezolid-Resistant Enterococci Kainer et al., Emerg Infect Dis, 2007;13:

19 Linezolid resistance due to ribosomal methylation The cfr gene encodes a rrna methylase, which transfers an additional methyl group to A2503 in 23S rrna Cfr impairs ribosomal binding of 5 different classes of antibiotics: phenicols lincosamides oxazolidinones pleuromutilins streptogramins A cfr is the first transferable gene for oxazolidinone and pleuromutilin resistance

20 Detection of linezolid Cfr resistance Arias et al, Antimicrob Agents Chemother, 2008, 46, 892

21 Transfer between animal and human staphylococci? Reported in Staphylococcus spp. of animal origin in Europe (Kehrenberg CF et al.. Antimicrob.Agents Chemother. 2007, 51: Kehrenberg C and S Schwarz. Antimicrob. Agents Chemother. 2006, 50: Long KS et al.. Antimicrob. Agents Chemother. 2006, 50: Schwarz, S., C. et al.. Antimicrob. Agents Chemother. 2000, 44:2530 3) And recently in staphylococci from humans. A unique human isolate in Colombia (Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin AS. Mol Microbiol. 2007;64: ) A linezolid-resistant MRSA and one MR S. epidermidis were recently isolated in the USA (Mendes RE, et al. Antimicrob Agents Chemother. 2008;52:2244-6)

22 Mobilisation of cfr cfr surrounding DNA sequences in animal S. aureus (pscf53) and human S. aureus ( X) and S. epidermidis ( L) isolates Mendes RE, et al. Antimicrob Agents Chemother. 2008;52:2244-6

23 The future of the «new» antimicrobials The «half-life» (in terms of clinical efficiency) of an antibiotic depends on numerous factors, including the existence of isolates with acquired resistance to the considered antibiotic at the starting point antibiotic usage the mechanism of resistance and the genetic support (plasmid..) Example of a recent modelisation for resistance to telithromycin (in pneumococci) (epidemiology and mechanisms of resistance known)

24 Opatowski L, Temime L, Varon E, Leclercq R, Drugeon H, Boëlle PY, Guillemot D. PLoS ONE. 2008;3:e2089 Antibiotic Innovation May Contribute to slowing the dissemination of MDR Streptococcus pneumoniae Times to reach 1% or 10% resistant strains among colonized individuals as a function of the rate of ketolide prescriptions

25 Conclusion Bacteria have already selected some specific ways to resist new antibiotics Tigecycline: efflux (Gram-positive and Gramnegative organisms Daptomycin: cell wall structure modification Linezolid: ribosomal target modification Resistant isolates are rare. Availibility of several antibiotic alternatives against MDR bacteria may delay the spread of resistance

Resistance to linezolid in enterococci and staphylococci referred to the national reference laboratory

Resistance to linezolid in enterococci and staphylococci referred to the national reference laboratory Resistance to linezolid in enterococci and staphylococci referred to the national reference laboratory Dr Danièle Meunier, AMRHAI BSAC - Antimicrobial Susceptibility Testing User Days Oxazolidinone Linezolid

More information

Cubicin (Daptomycin) Priv.Doz. Dr. med. Markus Rothenburger

Cubicin (Daptomycin) Priv.Doz. Dr. med. Markus Rothenburger Cubicin (Daptomycin) Priv.Doz. Dr. med. Markus Rothenburger Cubicin (Daptomycin): A new generation of antibiotics First-in-class cyclic natural lipopeptide Activity against major gram positive pathogens

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview

More information

Macrolides, Clindamycin & Ketolides Polymyxins

Macrolides, Clindamycin & Ketolides Polymyxins Macrolides, Clindamycin & Ketolides Polymyxins Kwan Soo Ko Macrolides - Erythromycin - Azithromycin - Clarithromycin Lincosamides - Lincomycin - Clindamycin Unrelated chemically But, many similar biological

More information

Identification and characterization of linezolid-resistant USA300 Staphylococcus aureus

Identification and characterization of linezolid-resistant USA300 Staphylococcus aureus AAC Accepts, published online ahead of print on 18 August 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.03380-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Identification

More information

First Report of Linezolid-resistant Staphylococcal Clinical Isolates in Mexico Caused by cfr: Evidence of in. Rodrigo E.

First Report of Linezolid-resistant Staphylococcal Clinical Isolates in Mexico Caused by cfr: Evidence of in. Rodrigo E. JCM Accepts, published online ahead of print on 2 June 2010 J. Clin. Microbiol. doi:10.1128/jcm.00880-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Mupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010

Mupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010 Mupirocin Rationale for the EUCAST clinical breakpoints, version 1.0 6 th July 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European

More information

life-threatening infections

life-threatening infections Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal

More information

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005 Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,

More information

Retapamulin Inhibition of Translation and ACCEPTED. 50S Ribosomal Subunit Formation in. Staphylococcus aureus Cells

Retapamulin Inhibition of Translation and ACCEPTED. 50S Ribosomal Subunit Formation in. Staphylococcus aureus Cells AAC Accepts, published online ahead of print on 11 June 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.00475-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Multicity Outbreak of Linezolid- Resistant Staphylococcus epidermidis Associated with Clonal Spread of a cfr-containing Strain

Multicity Outbreak of Linezolid- Resistant Staphylococcus epidermidis Associated with Clonal Spread of a cfr-containing Strain BRIEF REPORT Multicity Outbreak of Linezolid- Resistant Staphylococcus epidermidis Associated with Clonal Spread of a cfr-containing Strain Hector Bonilla, 1 Michael D. Huband, 3 Joan Seidel, 2 Helen Schmidt,

More information

Vancomycin Rationale for the EUCAST clinical breakpoints, version June 2010

Vancomycin Rationale for the EUCAST clinical breakpoints, version June 2010 Vancomycin Rationale for the EUCAST clinical breakpoints, version 2.1 17 June 2010 Introduction The glycopeptides are a class of agents composed of amino acid residues and attached sugars. Glycopeptides

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Frank Lowy Protein Synthesis Inhibitors This lecture discusses a diverse group of antibiotics that are grouped together because they all have a common mechanism of action they are protein synthesis inhibitors.

More information

Tedizolid Phosphate (Sivextro) A Second-Generation Oxazolidinone to Treat Acute Bacterial Skin and Skin Structure Infections

Tedizolid Phosphate (Sivextro) A Second-Generation Oxazolidinone to Treat Acute Bacterial Skin and Skin Structure Infections DrUG FOrECAST Tedizolid Phosphate (Sivextro) A Second-Generation Oxazolidinone to Treat Acute Bacterial Skin and Skin Structure Infections Elaine Wong, PharmD, BCPS; and Saba rab, PharmD, BCPS Dr. Wong

More information

Infectious Disease in the Critically Ill Patient

Infectious Disease in the Critically Ill Patient Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:

More information

Macrolides & Ketolides. Objectives. Protein Synthesis

Macrolides & Ketolides. Objectives. Protein Synthesis Macrolides & Ketolides Elizabeth D. Hermsen, Pharm.D. Infectious Diseases Research Fellow University of Minnesota College of Pharmacy bjectives Participant should be able to explain macrolide/ketolide

More information

Paul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute

Paul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute New antimicrobials Paul M. Tulkens Françoise Van Bambeke Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute Université catholique de Louvain,, Brussels, Belgium Slides are

More information

Options for Complicated Skin and Skin Structure Infections. Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ.

Options for Complicated Skin and Skin Structure Infections. Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Options for Complicated Skin and Skin Structure Infections Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator for,

More information

INTRODUCTION. Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; 2

INTRODUCTION. Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; 2 New Microbiologica, 39, 4, 269-273, 2016, ISN 1121-7138 FULL PAPER Resistance to linezolid in Staphylococcus spp. clinical isolates associated with ribosomal binding site modifications: novel mutation

More information

A Novel Lantibiotic Acting on Bacterial Cell Wall Synthesis Produced by the Uncommon FLAVIA MARINELLI. DBSM, University of Insubria, Varese Italy

A Novel Lantibiotic Acting on Bacterial Cell Wall Synthesis Produced by the Uncommon FLAVIA MARINELLI. DBSM, University of Insubria, Varese Italy A Novel Lantibiotic Acting on Bacterial Cell Wall Synthesis Produced by the Uncommon Actinomycete Planomonospora sp. FLAVIA MARINELLI DBSM, University of Insubria, Varese Italy Vicuron Pharmaceuticals,

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Macrolides - Lincosamides Aminoglycosides Tetracyclines Chloramphenicol Oxazolidinones Streptogramins Lecture Outline Description of protein synthesis - translation Antibiotics

More information

Spectrum of vancomycin and susceptibility testing

Spectrum of vancomycin and susceptibility testing Spectrum of vancomycin and susceptibility testing Olivier Denis Service de Microbiologie Laboratoire de bactériologie Service de Microbiologie Hôpital Erasme Glycopeptides Vancomycin 1958 < Amycolatopsis

More information

Other β-lactam. A. Carbapenems:

Other β-lactam. A. Carbapenems: A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,

More information

Protein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8

Protein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human

More information

ALTARGO TM Retapamulin. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w)

ALTARGO TM Retapamulin. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) ALTARGO TM Retapamulin QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) PHARMACEUTICAL FORM Ointment. CLINICAL PARTICULARS Indications ALTARGO (retapamulin) 1% ointment is indicated

More information

Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone

Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone Zurenko et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:46 RESEARCH Open Access Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens

More information

Antibiotic Resistance of Non- pneumococcal Streptococci and Its Clinical Impact

Antibiotic Resistance of Non- pneumococcal Streptococci and Its Clinical Impact Antibiotic Resistance of Non- pneumococcal Streptococci and Its Clinical Impact 50 Nainee Desai, Judith Steenbergen, and David E. Katz 1 Introduction The taxonomy of streptococci has undergone major changes

More information

Aminoglycosides. Not orally absorbed. Interact with negatively charged lipopolysaccharide on Gram- cell wall. Aminoglycoside properties

Aminoglycosides. Not orally absorbed. Interact with negatively charged lipopolysaccharide on Gram- cell wall. Aminoglycoside properties Aminoglycosides Tobramycin Kanamycin H2N Gentamicin Amikacin NHCOCHCH2CH2NH2 OH Aminoglycosides made of linked sugars. Decorated with many OH and NH2 groups, which render these compounds positively charged

More information

From the Structure and Function of the Ribosome to new Antibiotics

From the Structure and Function of the Ribosome to new Antibiotics From the Structure and Function of the Ribosome to new Antibiotics Crick s central dogma of molecular biology: DNA makes DNA makes RNA makes protein Jim Watson, 1964 J.A. Lake, 1976 (J.M.B. 105, 131)

More information

Linezolid - Tigecycline

Linezolid - Tigecycline Linezolid - Tigecycline Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Catholic University of Louvain, Brussels, Belgium With the support of Wallonie-Bruxelles-International

More information

Anti-Microbial Drugs

Anti-Microbial Drugs Name: Date: Monday March 7 th 2011 Class: I "Pharmacology Anti-Microbial Drugs Lecture 5 د. حيدر الشكرجي Macrolides: Anti-Microbial Drugs Erythromycin was the 1 st of macrolides to find clinical application,

More information

DIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05

DIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05 Date company submitted: 15 Dec 04 Date received by CDER: 15 Dec 04 Reviewer: Fred Marsik, Ph.D. Date assigned: 15 Dec 04 NAME AND ADDRESS OF APPLICANT Wyeth Pharmaceuticals Inc. P.O. Box 8299 Philadelphia,

More information

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe

More information

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC

More information

Steven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070

Steven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2063 2069 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.01569-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative

More information

Microbiology - Problem Drill 16: Antibiotics. Question No. 1 of 10. Question. Feedback. Question

Microbiology - Problem Drill 16: Antibiotics. Question No. 1 of 10. Question. Feedback. Question Microbiology - Problem Drill 16: Antibiotics No. 1 of 10 1. An effective chemotherapeutic drug should have. (A) Low therapeutic index (B) More toxicity (C) Selective toxicity (D) Mutation inducing properties

More information

With approval of the Common Belgian Medical Ethical platform - visa no. 13/V1/5871/054190

With approval of the Common Belgian Medical Ethical platform - visa no. 13/V1/5871/054190 Approaches to Current and Future Treatment ptions in Gram-positive Infections Paul M. Tulkens, MD, PhD Louvain Drug Research Institute Université catholique de Louvain Brussels, Belgium With approval of

More information

DRUG UTILIZATION EVALUATION

DRUG UTILIZATION EVALUATION DRUG UTILIZATION EVALUATION Prescribing Trends with Daptomycin (Cubicin) For the Treatment of Gram-Positive Infections Noreen H. Chan Tompkins, PharmD, and Stephen J. Harnicar, PharmD INTRODUCTION Daptomycin

More information

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010 Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European

More information

ResFinder 4.0: towards in silico antibiograms

ResFinder 4.0: towards in silico antibiograms ResFinder 4.0: towards in silico antibiograms Valeria Bortolaia, DVM, PhD Research group for Genomic Epidemiology National Food Institute Technical University of Denmark The path to WGS-based AMR prediction

More information

Overview of Translation (2) Protein Synthesis Inhibitors. Overview of Translation (3) Lecture Outline. Overview of Translation (1)

Overview of Translation (2) Protein Synthesis Inhibitors. Overview of Translation (3) Lecture Outline. Overview of Translation (1) Protein Synthesis Inhibitors Macrolides - Lincosamides Aminoglycosides Tetracyclines Chloramphenicol Streptogramins Oxazolidinones Overview of Translation (2) Initiation trna + AA binds translation elongation

More information

In Vitro Susceptibility of Staphylococci and Enterococci to Vancomycin and Teicoplanin

In Vitro Susceptibility of Staphylococci and Enterococci to Vancomycin and Teicoplanin In Vitro Susceptibility of Staphylococci and Enterococci to Vancomycin and Teicoplanin 19 A. Guzek, K. Korzeniewski, Aneta Nitsch-Osuch, Z. Rybicki, and E. Prokop Abstract Hospital-acquired infections

More information

In Vitro Susceptibilities of Aerobic and Facultative Non-Spore- Forming Gram-Positive Bacilli to HMR 3647 (RU 66647) and 14 Other Antimicrobials

In Vitro Susceptibilities of Aerobic and Facultative Non-Spore- Forming Gram-Positive Bacilli to HMR 3647 (RU 66647) and 14 Other Antimicrobials ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1028 1033 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Susceptibilities of Aerobic and Facultative

More information

THE STRONGEST RESISTANCE OF Staphylococcus aureus TO ERYTHROMYCIN IS CAUSED BY DECREASING UPTAKE OF THE ANTIBIOTIC INTO THE CELLS

THE STRONGEST RESISTANCE OF Staphylococcus aureus TO ERYTHROMYCIN IS CAUSED BY DECREASING UPTAKE OF THE ANTIBIOTIC INTO THE CELLS CELLULAR & MOLECULAR BIOLOGY LETTERS http://www.cmbl.org.pl Received: 06 February 2012 Volume 17 (2012) pp 633-645 Final form accepted: 07 September 2012 DOI: 10.2478/s11658-012-0034-3 Published online:

More information

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003 NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and

More information

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity

More information

ALTARGO. Retapamulin. Retapamulin 10 mg per gram (1% w/w)

ALTARGO. Retapamulin. Retapamulin 10 mg per gram (1% w/w) ALTARGO Retapamulin 1. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) 2. PHARMACEUTICAL FORM Ointment 3. CLINICAL PARTICULARS 3.1 Indications Retapamulin is indicated for

More information

Received 30 May 2004/Returned for modification 31 August 2004/Accepted 25 September 2004

Received 30 May 2004/Returned for modification 31 August 2004/Accepted 25 September 2004 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2005, p. 408 413 Vol. 49, No. 1 0066-4804/05/$08.00 0 doi:10.1128/aac.49.1.408 413.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.

More information

VISA infections. Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis

VISA infections. Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis VISA infections Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis jeanralph.zahar@aphp.fr H VISA and VISA infections Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis

More information

Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects

Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,

More information

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides Clin Pharmacokinet (2018) 57:797 816 https://doi.org/10.1007/s40262-017-0623-4 REVIEW ARTICLE Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides Valentin

More information

Antibiotic Classification Antibiotic Classification and Modes of Action

Antibiotic Classification Antibiotic Classification and Modes of Action and Modes of Action Part # 60-00415-0 1 biomérieux, the blue logo and VITEK are used, pending and/or registered trademarks belonging to biomérieux SA or one of its subsidiaries. CLSI is a registered trademark

More information

pharmaceuticals ISSN

pharmaceuticals ISSN Pharmaceuticals 2010, 3, 1988-2006; doi:10.3390/ph3071988 Review OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Linezolid Resistance in Staphylococci Stefania Stefani *,

More information

Supporting Information

Supporting Information Supporting Information Discovery of linear low-cationic peptides to target methicillin-resistant Staphylococcus aureus in vivo Yuan Liu, Meirong Song, Shuangyang Ding,, Kui Zhu*,,, Beijing Advanced Innovation

More information

New Antimicrobials: Now and In the Future

New Antimicrobials: Now and In the Future New Antimicrobials: Now and In the Future David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Conflicts of Interest Melinta

More information

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

More information

SURVEILLANCE FOR GLYCOPEPTIDE-RESISTANT ENTEROCOCCI

SURVEILLANCE FOR GLYCOPEPTIDE-RESISTANT ENTEROCOCCI SURVEILLANCE FOR GLYCOPEPTIDE-RESISTANT ENTEROCOCCI Drs N Bosman, T Nana & C Sriruttan CMID NHLS Dr Charlotte Sriruttan SASCM 3/11 GLOBAL DATA VRE first isolated in Europe in 1987, (Leclercq R., et al

More information

Pharmacodynamic indices in targeting therapy of critical infections

Pharmacodynamic indices in targeting therapy of critical infections Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective

More information

Multi-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis

Multi-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin

More information

Author: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents

Author: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN

More information

Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)

Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011) b r a z j i n f e c t d i s. 2 0 1 3;1 7(6):672 681 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original article Susceptibility rates in Latin American nations: report from

More information

Surveillance of Enterococci in Belgium. M. Ieven, K. Loens, B. Jans and H. Goossens

Surveillance of Enterococci in Belgium. M. Ieven, K. Loens, B. Jans and H. Goossens Surveillance of Enterococci in Belgium M. Ieven, K. Loens, B. Jans and H. Goossens Surveillance of Enterococci in Belgium Overview Introduction and epidemiological surveillance Results of isolates received

More information

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,

More information

Tedizolid Phosphate: a Next-Generation Oxazolidinone

Tedizolid Phosphate: a Next-Generation Oxazolidinone Infect Dis Ther (2015) 4:1 14 DOI 10.1007/s40121-015-0060-3 REVIEW Tedizolid Phosphate: a Next-Generation Oxazolidinone Jeffrey M. Rybak Karrine Roberts To view enhanced content go to www.infectiousdiseases-open.com

More information

Evidence for the use of new and old agents for MRSA infection. Dr Charis Marwick Ninewells Hospital & Medical School Dundee

Evidence for the use of new and old agents for MRSA infection. Dr Charis Marwick Ninewells Hospital & Medical School Dundee Evidence for the use of new and old agents for MRSA infection Dr Charis Marwick Ninewells Hospital & Medical School Dundee 32 year old man Admitted unwell for few days Cough, fever, short of breath, pleuritic

More information

ANTIMICROBIAL SUSCEPTIBILITY COAGULASE-NEGATIVE STAPHYLOCOCCI CAUSING SERIOUS BACTEREMIC EPISODES IN CHILDREN

ANTIMICROBIAL SUSCEPTIBILITY COAGULASE-NEGATIVE STAPHYLOCOCCI CAUSING SERIOUS BACTEREMIC EPISODES IN CHILDREN SERIOUS BACTEREMIC EPISODES IN CHILDREN Sample ES-02 (2016) was a simulated blood culture isolate from a neonate with sepsis. The sample was sent for organism identification and antimicrobial susceptibility

More information

Vancomycin. A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci.

Vancomycin. A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci. Vancomycin A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci. Used IV in treating endocarditis caused by methicillin-resistant

More information

Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves

Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves Veterinary and Agrochemical Research Centre Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves P. Butaye 1 Introduction Enterococci are regarded as

More information

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,

More information

SMALL GROUP PROBLEM SOLVING SESSION GENETICS

SMALL GROUP PROBLEM SOLVING SESSION GENETICS SMALL GOU OBLEM SOLVING SESSION GENETICS DATE: Thursday, August 28, 2014 8:30am 10:30 am LEANING GOAL By attending and participating in this Small Group roblem Solving Session, you will be able to describe

More information

Topical antimicrobial agents in wound care. Professor Val Edwards-Jones Manchester Metropolitan University UK

Topical antimicrobial agents in wound care. Professor Val Edwards-Jones Manchester Metropolitan University UK Topical antimicrobial agents in wound care Professor Val Edwards-Jones Manchester Metropolitan University UK Antimicrobial agents Antibacterial agents Antifungal agents Antiviral agents Antiparasitic agents?others

More information

Resistance to Polymyxins in France

Resistance to Polymyxins in France Resistance to Polymyxins in France Paris Prof. Patrice Nordmann NDM producers in Enterobacteriaceae The polymyxins; colistin and polymyxin B Colistin - Synthesis by Bacillus polymyxa spp colistinus -

More information

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties

More information

SCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past

SCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated

More information

Daptomycin versus vancomycin in the treatment of methicillin-resistant. Staphylococcus aureus meningitis in experimental rabbit model.

Daptomycin versus vancomycin in the treatment of methicillin-resistant. Staphylococcus aureus meningitis in experimental rabbit model. AAC Accepts, published online ahead of print on 14 January 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01996-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Daptomycin

More information

telithromycin oral streptococci 140 telithromycin TEL azithromycin AZM clarithromycin CAM roxithromycin RXM levofloxacin LVFX ampicillin ABPC

telithromycin oral streptococci 140 telithromycin TEL azithromycin AZM clarithromycin CAM roxithromycin RXM levofloxacin LVFX ampicillin ABPC telithromycin 3 0 3 0 oral streptococci 0 telithromycintelazithromycin AZMclarithromycinCAMroxithromycinRXMlevofloxacinLVFXampicillinABPC erythromycinem TEL EM erm mef 5 Streptococcus mitis MIC90 ml TEL

More information

Daptomycin in Clinical Practice. Paolo Grossi

Daptomycin in Clinical Practice. Paolo Grossi Clinica delle Malattie Infettive e Tropicali Università degli Studi dell Insubria Ospedale di Circolo e Fondazione Macchi, Varese Second Opinion Infettivologica Centro Nazionale Trapianti, ISS, Roma Daptomycin

More information

Issues Abx request. Sneezing w/ post- nasal d/c & redness mucous membranes Throat. Chest px w/ coughing, difficulty breathing

Issues Abx request. Sneezing w/ post- nasal d/c & redness mucous membranes Throat. Chest px w/ coughing, difficulty breathing Week 5 Magic Bullets URTI + Pneumonia Presenting Sx Cough, sore throat & runny nose Aches & pains all over Shivers & fevers Respiratory Viruses Viruses causing flu Influenza A/B/C (orthomyxovirus) Respiratory

More information

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition

More information

number Done by Corrected by Doctor Hamed Al Zoubi

number Done by Corrected by Doctor Hamed Al Zoubi number 8 Done by م ها أبو عجمي ة Corrected by Mamoon Alqtamin Doctor Hamed Al Zoubi The last page includes definitions for the underlined asterisked words *, You can skip Extra notes, Enjoy! A Brief Introduction

More information

Overview of Tigecycline and Its Role in the Era of Antibiotic Resistance

Overview of Tigecycline and Its Role in the Era of Antibiotic Resistance BJID 2006; 10 (June) 203 Overview of Tigecycline and Its Role in the Era of Antibiotic Resistance Flávia Rossi, Denise Andreazzi University of São Paulo, LIM 03; São Paulo, SP, Brazil The increasing antimicrobial

More information

TELITHROMYCIN (KETEK ) A NEW ANTIMICROBIAL AGENT

TELITHROMYCIN (KETEK ) A NEW ANTIMICROBIAL AGENT Volume 19, Issue 12 September 2004 TELITHROMYCIN (KETEK ) A NEW ANTIMICROBIAL AGENT Christopher Cha, Pharm.D. Candidate Introduction Infections that invade the lower respiratory tract, such as community-acquired

More information

New Insights into Peptidoglycan Biosynthesis. Louis B. Rice Warren Alpert Medical School of Brown University Providence, RI

New Insights into Peptidoglycan Biosynthesis. Louis B. Rice Warren Alpert Medical School of Brown University Providence, RI New Insights into Peptidoglycan Biosynthesis Louis B. Rice Warren Alpert Medical School of Brown University Providence, RI Outline of Presentation Review role of penicillin-binding proteins in cell wall

More information

Mécanismes d adaptation et de Résistance de Pseudomonas aeruginosa à la colistine dans la mucoviscidose

Mécanismes d adaptation et de Résistance de Pseudomonas aeruginosa à la colistine dans la mucoviscidose Mécanismes d adaptation et de Résistance de Pseudomonas aeruginosa à la colistine dans la mucoviscidose Jeannot K, Nogues A, Dutruel T, Plésiat P National Reference Centre for Antibiotic Resistance Department

More information

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336

More information

This article was published in an Elsevier journal. The attached copy is furnished to the author for non-commercial research and education use, including for instruction at the author s institution, sharing

More information

Mesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections

Mesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative

More information

Antibiotics acting on Protein Synthesis E. Westhof

Antibiotics acting on Protein Synthesis E. Westhof Antibiotics acting on Protein Synthesis E. Westhof 1. Considérations générales et introductives 1 Facts about Antibiotics Alexander Fleming (1928) discovered penicillin Ignored until early 1940s with extensive

More information

Rapid identification and resistance assessment: The future is mass spectrometry

Rapid identification and resistance assessment: The future is mass spectrometry Rapid identification and resistance assessment: The future is mass spectrometry Dr Sanmarié Schlebusch Director of Microbiology Mater Pathology Brisbane Outline Introduction Plug and play Pre-prep and

More information

Dissemination of Macrolide-Resistant Streptococcus pneumoniae Isolates Containing Both erm(b) and mef(a) in South Korea

Dissemination of Macrolide-Resistant Streptococcus pneumoniae Isolates Containing Both erm(b) and mef(a) in South Korea JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2003, p. 5787 5791 Vol. 41, No. 12 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.12.5787 5791.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.

More information

Disclosure. Patient Case. Objectives. Patient Case. Patient Case 7/25/2015. An update on the treatment of skin and soft tissue infections

Disclosure. Patient Case. Objectives. Patient Case. Patient Case 7/25/2015. An update on the treatment of skin and soft tissue infections Disclosure 49th Annual Meeting An update on the treatment of skin and soft tissue infections I do not have a vested interest in or affiliation with any corporate organization offering financial support

More information

Skin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more)

Skin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more) Skin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more) Christian Eckmann Antibiotic Stewardship Expert ECDC Chief of Staff Department of General, Visceral and Thoracic Surgery Klinikum

More information

Cubicin A Guide to Dosing

Cubicin A Guide to Dosing Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections

More information

Sep Oct Nov Dec Total

Sep Oct Nov Dec Total LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0

More information

HOW AND WHY GENES ARE REGULATED HOW AND WHY GENES ARE REGULATED. Patterns of Gene Expression in Differentiated Cells

HOW AND WHY GENES ARE REGULATED HOW AND WHY GENES ARE REGULATED. Patterns of Gene Expression in Differentiated Cells HOW AND WHY GENES ARE REGULATED 5 HOW AND WHY GENES ARE REGULATED 6 Every somatic cell in an organism contains identical genetic instructions. They all share the same genome. So what makes cells different

More information

Daptomycin Exerts Bactericidal Activity without Lysis of Staphylococcus aureus ACCEPTED. Silverman 1*

Daptomycin Exerts Bactericidal Activity without Lysis of Staphylococcus aureus ACCEPTED. Silverman 1* AAC Accepts, published online ahead of print on 31 March 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.01410-07 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.

More information

Vancomycin resistance in Staphylococcus aureus

Vancomycin resistance in Staphylococcus aureus INTERNATIONAL NEWSLETTER no 3 SEPTEMBER 2002 STATE-OF-THE-ART THE BIOMERIEUX SOLUTION DID YOU KNOW? PRACTICAL ADVICE Vancomycin resistance in Staphylococcus aureus VITEK 2 performance Web site 10 th ISSSI

More information

Prokaryotes and eukaryotes alter gene expression in response to their changing environment

Prokaryotes and eukaryotes alter gene expression in response to their changing environment Chapter 18 Prokaryotes and eukaryotes alter gene expression in response to their changing environment In multicellular eukaryotes, gene expression regulates development and is responsible for differences

More information